{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:49:44Z","timestamp":1784893784613,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The aim of this study was to use clinical data to develop a prediction model for treatment response, comparing tofacitinib to methotrexate or etanercept in individual patients with Psoriatic Arthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Data from the development cohort (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200980) of the TOFA-PREDICT trial were used. The cohort included PsA patients na\u00efve to disease-modifying antirheumatic drugs (DMARDs) randomised to tofacitinib (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920) or methotrexate (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920), and patients failing conventional synthetic DMARD (csDMARD) treatment randomised to add-on tofacitinib (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920) or etanercept (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920). Treatment response was defined as achievement of minimal disease activity at week 16. Elastic net regression was used to select relevant baseline predictors in the complete cohort and in treatment subgroups. Using Ridge regression with different modelling strategies, three prediction models were developed and compared. Based on performance, a final model was selected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Increased Health Assessment Questionnaire score, increased tender joint count, increased Leeds Enthesitis Index score, decreased VAS global assessment by physician and previous Tumour Necrosis Factor alpha inhibitor treatment were selected as predictors for non-response. The final cross-validated model had an AUC-ROC of 0.76 and predicted clinically relevant differences in response to the compared treatments. The predicted probability of response was higher for methotrexate compared to tofacitinib in 85% of DMARD na\u00efve patients. The predicted probability of response was higher for etanercept compared to tofacitinib in all patients failing csDMARD treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results support the use of baseline clinical data for prediction of response to different treatments. We intend to validate this prediction model and to assess the additional predictive value of imaging and multi-omics biomarkers in future analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>EudraCT Trial registration number 2017\u2013003900-28, registration date January 25th 2018.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-025-03660-2","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:31:54Z","timestamp":1761568314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The development of a clinical prediction model for response to methotrexate, tofacitinib, and etanercept in patients with Psoriatic Arthritis"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7331-0104","authenticated-orcid":false,"given":"F. T.","family":"Perton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5054-1569","authenticated-orcid":false,"given":"M. L. M.","family":"Bentvelzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7507-5002","authenticated-orcid":false,"given":"S.","family":"Fadaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1818-7833","authenticated-orcid":false,"given":"J. N.","family":"Pouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2546-312X","authenticated-orcid":false,"given":"J.","family":"Spierings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3792-7718","authenticated-orcid":false,"given":"H. E.","family":"Vonkeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7517-7348","authenticated-orcid":false,"given":"S. C.","family":"Mooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6379-1240","authenticated-orcid":false,"given":"L. G.","family":"Schipper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"TOFA-PREDICT author group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavish J.","family":"Bhansing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radjesh J.","family":"Bisoendial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra T.A.","family":"van Bijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenny","family":"van Bon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoaneta C.","family":"Comarniceanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z. Nazira","family":"Jahangier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim L.T.A.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline S.L","family":"Kloth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc R.","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arno W. R.","family":"van Kuijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmerik F.A.","family":"Leijten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasti C.","family":"Mooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia G.","family":"Schipper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid M.","family":"van Tubergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald E.","family":"Vonkeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone A.","family":"Vreugdenhil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siska","family":"Wijngaarden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8825-6486","authenticated-orcid":false,"given":"S. C.","family":"Mastbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2361-2803","authenticated-orcid":false,"given":"P. M. J.","family":"Welsing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"3660_CR1","doi-asserted-by":"crossref","unstructured":"Goulabchand R, Mouterde G, Barnetche T, Lukas C, Morel J, Combe B. Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis. 2013;73(2):414.","DOI":"10.1136\/annrheumdis-2012-202641"},{"key":"3660_CR2","doi-asserted-by":"crossref","unstructured":"Haroon M, Gallagher P, Fitzgerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2014;74(6):1045.","DOI":"10.1136\/annrheumdis-2013-204858"},{"issue":"2","key":"3660_CR3","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","volume":"74","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74(2):326\u201332.","journal-title":"Ann Rheum Dis"},{"key":"3660_CR4","doi-asserted-by":"crossref","unstructured":"Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465.","DOI":"10.1038\/s41584-022-00798-0"},{"key":"3660_CR5","doi-asserted-by":"crossref","unstructured":"Fitzgerald O, Ogdie A, Chandran V, Coates LC, Kavanaugh A, Tillett W, et al. Psoriatic arthritis. Nat Rev Dis Primers. 2021;7(1):59.","DOI":"10.1038\/s41572-021-00293-y"},{"issue":"1","key":"3660_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3899\/jrheum.220315","volume":"50","author":"Y Leung","year":"2023","unstructured":"Leung Y, Korotaeva TV, Candia L, Pedersen SJ, Bautista Molano W, Ruderman EM, et al. Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. J Rheumatol. 2023;50(1):119\u201330.","journal-title":"J Rheumatol"},{"key":"3660_CR7","doi-asserted-by":"crossref","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706\u201319.","DOI":"10.1136\/ard-2024-225534"},{"key":"3660_CR8","doi-asserted-by":"crossref","unstructured":"Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.\u00a0Arthritis Rheumatol. 2018;71(1):5.","DOI":"10.1002\/art.40726"},{"key":"3660_CR9","doi-asserted-by":"crossref","unstructured":"Kleinrensink NJ, Perton FT, Pouw JN, Vincken NLA, Hartgring SAY, Jansen MP, et al. TOFA-PREDICT study protocol: a stratification trial to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in psoriatic arthritis (PsA). BMJ Open. 2022;12(10):e064338.","DOI":"10.1136\/bmjopen-2022-064338"},{"key":"3660_CR10","doi-asserted-by":"crossref","unstructured":"Iervolino S, Di Minno MND, Peluso R, Lofrano M, Russolillo A, Di Minno G, et al. Predictors of Early Minimal Disease Activity in Patients with Psoriatic Arthritis Treated with Tumor Necrosis Factor-\u03b1 Blockers. J Rheumatol. 2012;39(3):568.","DOI":"10.3899\/jrheum.110763"},{"key":"3660_CR11","doi-asserted-by":"crossref","unstructured":"Perrotta FM, Marchesoni A, Lubrano E. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-\u03b1 Drugs. J Rheumatol. 2015;43(2):350.","DOI":"10.3899\/jrheum.150805"},{"key":"3660_CR12","doi-asserted-by":"crossref","unstructured":"Haddad A, Thavaneswaran A, Ruiz\u2010arruza I, Pellett F, Chandran V, Cook RJ, et al. Minimal Disease Activity and Anti\u2013Tumor Necrosis Factor Therapy in Psoriatic Arthritis.\u00a0Arthritis Care Res. 2015;67(6):842.","DOI":"10.1002\/acr.22529"},{"key":"3660_CR13","doi-asserted-by":"crossref","unstructured":"Mease PJ, Kavanaugh A, Coates LC, Mcinnes IB, Hojnik M, Zhang Y, et al. Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial.\u00a0Rheum\u00a0Musculoskelet\u00a0Dis\u00a0Open. 2017;3(1):e000415.","DOI":"10.1136\/rmdopen-2016-000415"},{"issue":"1","key":"3660_CR14","first-page":"107","volume":"38","author":"R Scrivo","year":"2020","unstructured":"Scrivo R, Giardino AM, Salvarani C, Foti R, Afeltra A, Viapiana O, et al. An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab. Clin Exp Rheumatol. 2020;38(1):107\u201314.","journal-title":"Clin Exp Rheumatol"},{"key":"3660_CR15","doi-asserted-by":"crossref","unstructured":"Saber TP, Ng CT, Renard G, Lynch BM, Pontifex E, Walsh CA, et al. Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther. 2010;12(3):R94.","DOI":"10.1186\/ar3021"},{"key":"3660_CR16","doi-asserted-by":"crossref","unstructured":"Magee C, Jethwa H, Fitzgerald OM, Jadon DR. Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review.\u00a0Ther\u00a0Adv\u00a0Musculoskelet\u00a0Dis. 2021;13:1759720X211.","DOI":"10.1177\/1759720X211014010"},{"issue":"8","key":"3660_CR17","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1136\/ard.2009.122259","volume":"69","author":"M Schoels","year":"2010","unstructured":"Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS. Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis. 2010;69(8):1441\u20137.","journal-title":"Ann Rheum Dis"},{"key":"3660_CR18","doi-asserted-by":"crossref","unstructured":"Luchetti Gentiloni MM, Paci V, Carletto A, Zabotti A, Ramonda R, Chimenti MS, et al. Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study. Arthritis Res Ther. 2023;25(1):1\u201311.","DOI":"10.1186\/s13075-023-03182-9"},{"key":"3660_CR19","doi-asserted-by":"crossref","unstructured":"Sheane BJ, Thavaneswaran A, Gladman DD, Chandran V. Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis. J Rheumatol. 2016;43(9):1718.","DOI":"10.3899\/jrheum.160111"},{"key":"3660_CR20","doi-asserted-by":"crossref","unstructured":"Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2009;69(01):48.","DOI":"10.1136\/ard.2008.102053"},{"key":"3660_CR21","doi-asserted-by":"crossref","unstructured":"Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis & Rheumatism. 2008;59(5):686.","DOI":"10.1002\/art.23568"},{"key":"3660_CR22","doi-asserted-by":"crossref","unstructured":"Hoogland J, Inthout J, Belias M, Rovers MM, Riley RD, E. Harrell Jr F, et al. A tutorial on individualized treatment effect prediction from randomized trials with a binary endpoint. Statistics in Medicine 2021;40(26):5961.","DOI":"10.1002\/sim.9154"},{"key":"3660_CR23","doi-asserted-by":"crossref","unstructured":"Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024.","DOI":"10.1136\/bmj-2023-078378"},{"key":"3660_CR24","unstructured":"R Core Team. R: A language and environment for statistical computing.\u00a0R Foundation for Statistical Computing, Vienna, Austria.\u00a0Available online at\u00a02018.\u00a0https:\/\/www.R-project.org\/."},{"key":"3660_CR25","doi-asserted-by":"crossref","unstructured":"Kristensen LE, Deodhar A, Leung Y, Vranic I, Mortezavi M, Fallon L, et al. Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data. Rheumatol Ther. 2024;11(3):487.","DOI":"10.1007\/s40744-024-00662-5"},{"issue":"5","key":"3660_CR26","first-page":"886","volume":"22","author":"MG Blackmore","year":"1995","unstructured":"Blackmore MG, Gladman DD, Husted J, Long JA, Farewell VT. Measuring health status in psoriatic arthritis: the health assessment questionnaire and its modification. J Rheumatol. 1995;22(5):886\u201393.","journal-title":"J Rheumatol"},{"key":"3660_CR27","doi-asserted-by":"crossref","unstructured":"Deighton CM, Surtees D, Walker DJ. Influence of the severity of rheumatoid arthritis on sex differences in health assessment questionnaire scores. Annals of the Rheumatic Diseases. 1992;51(4):473.","DOI":"10.1136\/ard.51.4.473"},{"key":"3660_CR28","doi-asserted-by":"crossref","unstructured":"Brikman S, Furer V, Wollman J, Borok S, Matz H, Polachek A, et al. The Effect of the Presence of Fibromyalgia on Common Clinical Disease Activity Indices in Patients with Psoriatic Arthritis: A Cross-sectional Study. J Rheumatol. 2016;43(9):1749.","DOI":"10.3899\/jrheum.151491"},{"key":"3660_CR29","doi-asserted-by":"crossref","unstructured":"Feced Olmos CM, Alvarez-Calderon O, Herv\u00e1s Mar\u00edn D, Ivorra Cort\u00e9s J, Pujol Marco C, Rom\u00e1n Ivorra JA. Relationship between structural damage with loss of strength and functional disability in psoriatic arthritis patients. Clinical Biomechanics. 2019;68:169.","DOI":"10.1016\/j.clinbiomech.2019.06.009"},{"key":"3660_CR30","doi-asserted-by":"crossref","unstructured":"Fagerli KM, Lie E, Van Der Heijde D, Heiberg MS, Kalstad S, R\u00f8devand E, et al. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. Ann Rheum Dis. 2013;72(11):1840.","DOI":"10.1136\/annrheumdis-2012-203018"},{"key":"3660_CR31","doi-asserted-by":"crossref","unstructured":"Pajouheshnia R, Groenwold RHH, Peelen LM, Reitsma JB, Moons KGM. When and how to use data from randomised trials to develop or validate prognostic models. BMJ. 2019;365:l2154.","DOI":"10.1136\/bmj.l2154"},{"key":"3660_CR32","doi-asserted-by":"crossref","unstructured":"Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models via Coordinate Descent. J\u00a0Stat\u00a0Softw. 2010;33(1):1\u201322.","DOI":"10.18637\/jss.v033.i01"},{"key":"3660_CR33","doi-asserted-by":"crossref","unstructured":"Lewis MJ, Spiliopoulou A, Goldmann K, Pitzalis C, Mckeigue P, Barnes MR. nestedcv: an R package for fast implementation of nested cross-validation with embedded feature selection designed for transcriptomics and high-dimensional data.\u00a0Bioinformatics\u00a0Adv. 2023;3(1):vbad048.","DOI":"10.1093\/bioadv\/vbad048"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03660-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03660-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03660-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T11:04:36Z","timestamp":1761908676000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-025-03660-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3660"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03660-2","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Reported in open protocol publication [\n                      \n                      ].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HEV: paid consultant for Abbvie, Novartis, Pfizer, UCB, Johnson and Johnson. Financial grants from (pharmaceutical) companies: Galapagos and Boehringer Ingelheim AWRVK: Paid consultant for Janssen, Novartis and UCB. Financial grants from Novartis and UCB.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"197"}}